OakChart

CervoMed Inc

CRVOHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.77+0.40 (29.20%)
2026-11-12 06:45 CET
Market cap
26.78 USD m
Revenue, TTM
0.01 USD m
Net income, TTM
-28.52 USD m
Free cash flow, TTM
-26.59 USD m
EPS diluted, TTM
-2.77
P/E
-
Compare

Price

CRVO against its 20, 50 and 200-day averages
2050200beatmiss
Patternshover a marker to name it
2.004.006.008.00100.3M200.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CRVOclose 1.7720-day 1.9150-day 2.38200-day 3.311.7752w low

82.3% under the 52-week high of 10.00 on 28 Nov 2025. 52-week low 1.27 on 6 Nov 2026. Last 15 sessions, 85.0% high to low

Volume 34.51× normal · the line is the 50-bar volume average

Profile

CRVO
52-week range, 6% of the way up
1.2710.00

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.

Employees15
IPOOct 17, 2003
Beta-0.64
ATR, 14d0.23
Rel volume34.51
Short float12.49%
Insider own35.84%
Inst own22.70%

Snapshot

6 groups

Valuation

Index-
Market Cap26.78M
Enterprise Value7.18M
Income-28.52M
Sales0.01M
Book/sh1.15
Cash/sh1.30
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPOOct 17, 2003

Ratios

P/E-
Forward P/E-
PEG-
P/S2678.26
P/B1.54
P/C1.37
P/FCF-
EV/EBITDA-
EV/Sales718.26
Quick Ratio5.26
Current Ratio5.26
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.77
EPS next Y-1.32
EPS next Q-0.40
EPS this Y31.34%
EPS next Y35.31%
EPS next 5Y28.27%
EPS past 3/5Y35.66% 33.23%
Sales past 3/5Y- -
EPS Y/Y TTM4.48%
Sales Y/Y TTM-99.86%
EPS Q/Q53.31%
Sales Q/Q-100.00%
EarningsNov 09 BMO
EPS/Sales Surpr.17.89% -

Ownership

Insider Own35.84%
Insider Trans21.39%
Inst Own22.70%
Inst Trans-1.08%
ROA-109.81%
ROE-131.52%
ROIC-164.32%
Gross Margin-
Oper. Margin-334924.87%
Profit Margin-326822.54%
SMA20-7.31%
SMA50-25.51%
SMA200-46.49%
Trades-

Technical

Shs Outstand15.12M
Shs Float9.71M
Short Float12.49%
Short Ratio4.19
Short Interest1.21M
52W High10.00 -82.30%
52W Low1.27 39.37%
Volatility19.86% 11.60%
ATR (14)0.23
RSI (14)42.09
Beta-0.64
Rel Volume34.51
Avg Volume289.48K
Volume9,990,835

Performance

Perf Week13.46%
Perf Month-22.03%
Perf Quarter-39.59%
Perf Half Y-52.42%
Perf YTD-77.59%
Perf Year-74.61%
Perf 3Y-82.03%
Perf 5Y-94.41%
Perf 10Y-99.96%
Recom1.00
Target Price14.80
Prev Close1.37
Price1.77
Change %29.20%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Dec 18, 2025InitiatedCCantor FitzgeraldOverweight
Mar 13, 2025UpgradeCChardan Capital MarketsNeutral → Buy$14+691.0%
Dec 17, 2024DowngradeHH.C. WainwrightBuy → Neutral
Dec 11, 2024DowngradeMMorgan StanleyOverweight → Underweight
Dec 11, 2024DowngradeCChardan Capital MarketsBuy → Neutral
Dec 10, 2024DowngradeDD. Boral CapitalBuy → Hold
Dec 06, 2024InitiatedRROTH MKMBuy$45+2,442.4%
Dec 05, 2024InitiatedHH.C. WainwrightBuy$42+2,272.9%
Sep 18, 2024InitiatedCChardan Capital MarketsBuy$55+3,007.3%
Jul 26, 2024InitiatedMMorgan StanleyOverweight$35+1,877.4%

Peers

Mkt cap
TickerCompanyMkt cap
CGTXCognition Therapeutics Inc64.42M
ANVSAnnovis Bio Inc36.41M
AVXLAnavex Life Sciences Corp98.26M
ACIUAC Immune SA230.01M
ABOSAcumen Pharmaceuticals Inc16.64M
ACOGAlpha Cognition Inc187.72M
ATHEAlterity Therapeutics Ltd ADR44.12M
INMBINmune Bio Inc34.05M
PMNProMIS Neurosciences Inc33.72M
ALZNAlzamend Neuro Inc6.32M

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BOGER JOSHUA SDirectorJun 11 '26Buy3.14955,4143,000,0001,795,865Jun 15 05:37 PM
Winton MatthewChief Commercial and BusinessNov 17 '25Buy8.433,50029,50513,500Nov 19 07:46 AM
Winton MatthewChief Commercial and BusinessNov 18 '25Buy7.951,50011,92515,000Nov 19 07:46 AM
Gregoire SylvieDirectorNov 17 '25Buy8.4610,80791,42712,500Nov 19 07:45 AM
Gregoire SylvieDirectorNov 17 '25Buy8.4610,79391,3091,484,078Nov 19 07:45 AM
ELDER WILLIAM ROBERTCFO, GC & SecretaryNov 18 '25Buy8.322,50020,80012,500Nov 19 07:45 AM
ELDER WILLIAM ROBERTCFO, GC & SecretaryNov 17 '25Buy8.451,0008,45010,000Nov 19 07:45 AM
ALAM JOHN JCEO & PresidentNov 17 '25Buy8.4610,80791,4271,484,078Nov 19 07:45 AM
ALAM JOHN JCEO & PresidentNov 17 '25Buy8.4610,79391,30912,500Nov 19 07:45 AM
Gregoire SylvieDirectorNov 13 '25Buy7.514,44733,3971,471,578Nov 17 09:02 AM
Gregoire SylvieDirectorNov 14 '25Buy7.571,70712,9221,473,285Nov 17 09:02 AM
Gregoire SylvieDirectorNov 14 '25Buy7.551,69312,7821,693Nov 17 09:02 AM
ALAM JOHN JCEO & PresidentNov 13 '25Buy7.514,44733,3971,471,578Nov 17 09:01 AM
ALAM JOHN JCEO & PresidentNov 14 '25Buy7.571,70712,9221,707Nov 17 09:01 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally (Stocktwits) +11.29%
  • CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO) (InvestorsHub)
  • Why Did CRVO Stock Crash 22% In Pre-Market Trading Today? (Stocktwits) -22.15%
  • CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies (GlobeNewswire)
  • CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting (GlobeNewswire)
  • CervoMed Announces New Data at the AD/PD 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology (GlobeNewswire)
  • CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +5.10%
  • CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference (GlobeNewswire)
  • CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies (GlobeNewswire)
  • Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? (Zacks)
  • CervoMed's neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis (GlobeNewswire) +8.59%
  • CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies (GlobeNewswire) +9.42%
  • CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) (GlobeNewswire) -10.85%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.390-0.475-0.3900.000.006
2026Q22026-08-10-0.640-0.839-0.6400.000.056
2026Q12026-05-18-0.860-0.786-0.8600.000.078
2025Q42026-03-17-0.880-0.866-0.8740.010.098
2025Q32025-11-10-0.840-0.657-0.8350.321.217
2025Q22025-08-11-0.700-0.615-0.6991.761.396
2025Q12025-05-12-0.560-0.628-0.5621.921.726
2024Q42025-03-17-0.786-0.634-0.7992.161.537
2024Q32024-11-12-0.550-0.412-0.5461.942.305
2024Q22024-08-12-0.270-0.306-0.2663.291.585
2024Q12024-05-15-0.410-0.390-0.4082.352.352
2023Q42024-04-010.000-0.620-0.4162.501.002
2023Q32023-11-13-0.700-0.950-0.6981.530.001
2023Q22023-08-21-3.040--1.5540.00--
2021Q32021-11-10---8.978---
2020Q32020-11-12---5.201---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-615.75-544.13-615.850.000.00
2019FY-132-94.125-131.950.000.00
2020FY-22.500-19.500-22.4810.000.00
2021FY-18.750--18.5110.000.00
2023FY-0.820-3.565-0.8167.144.35
2024FY-2.020-1.853-2.0189.749.38
2025FY-2.980-2.974-2.9804.013.59
2026FY--2.046--0.00
2027FY--1.324--0.70
2028FY--1.100--0.00
2029FY--0.650--6.74
2030FY--2.340--68.20

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-096010.000.000.00
2026Q4S2026-11-066010.000.000.00
2026Q4S2026-10-256000.080.000.50
2026Q4S2026-08-116010.080.000.50
2026Q4S2026-08-106000.130.000.80
2026Q4S2026-08-056000.130.000.80
2026Q4S2026-07-306010.130.000.80
2026Q4S2026-05-227010.110.000.80
2026Q4S2026-05-187010.140.001.00
2026Q4S2026-03-177010.140.001.00
2026Q4S2026-03-168010.130.001.00
2026Q4S2026-03-137000.210.001.50
2026Q4S2025-12-176000.250.001.50
2026Q4S2025-11-125000.300.001.50

Estimate history

EPS, annual-2182.5-615.852-131.954-22.481-18.511-11.2-0.816-2.018-2.982-2.7657
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.546-0.799-0.562-0.699-0.835-0.874-0.86-0.642-0.39
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000007.1459.7384.0070.01
Period201720182019202020212022202320242025TTM
Sales, quarterly1.942.1621.9171.7580.3230.009000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0130.0450.4460.8541.3590.5185.6758.7039.25315.119
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.2548.7038.7039.2539.2539.2539.25913.52615.119
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.014.019.747.140.000.000.000.000.00
Cost of Goods Sold Incl. D&A----0.000.090.100.100.11
Gross Profit----0.00-0.09-0.10-0.10-0.11
Selling, General and Administrative Excl. Other29.2332.3027.9714.963.4815.9415.8711.4511.92
Research and Development18.9721.8218.808.441.348.509.436.625.75
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-29.23-28.29-18.23-7.81-3.48-16.04-15.97-11.55-12.03
Interest Expense-0.000.000.000.000.000.00--
Unusual Expense0.000.000.00-5.422.398.640.000.006.93
Net Income Before Taxes-28.52-26.97-16.29-2.17-5.80-24.54-15.86-11.47-18.81
Income Taxes0.000.000.000.000.00-0.44-1.680.33-0.44
Consolidated Net Income-28.52-26.97-16.29-2.17-5.80-24.10-14.19-11.80-18.37
Net Income From Continuing Operations-28.52-26.97-16.29-2.17-5.80-24.10-14.19-11.80-18.37
Net Income-28.52-26.97-16.29-2.17-5.80-24.10-16.14-11.80-26.62
EPS (Recurring)-1.89-2.98-2.02-2.24-7.97-13.87-22.48-131.95-503.65
EPS (Basic, Before Extraordinaries)-2.77-2.98-2.02-0.82-11.20-18.51-22.48-131.95-615.85
EPS (Diluted)-2.77-2.98-2.02-0.82-11.20-18.51-22.48-131.95-615.85
EBITDA-29.23-28.29-18.23-7.81-3.48-15.94-15.87-11.45-11.92
Non-Operating Income (Expense)0.711.331.940.220.060.140.110.090.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.321.451.410.410.330.650.540.380.97
Price To Sales Ratio5,145.9717.831.942.84-----
Operating Margin-334,924.87-706.22-187.18-109.35-----
Net Margin-326,822.54-673.06-167.29-30.40-----
Shares Outstanding15.129.258.705.670.521.360.850.450.05
Market Capitalization26.7826.7819.3143.3010.3131.0850.8915.426.72

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.010.321.761.922.16
Cost of Goods Sold Incl. D&A0.000.000.00-----
Gross Profit0.000.000.00-----
Selling, General and Administrative Excl. Other6.106.688.118.348.378.377.229.40
Research and Development3.684.325.145.836.045.114.847.09
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.10-6.68-8.11-8.33-8.04-6.62-5.30-7.24
Interest Expense0.000.00-0.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-5.90-6.57-7.96-8.09-7.73-6.26-4.89-6.71
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.90-6.57-7.96-8.09-7.73-6.26-4.89-6.71
Net Income From Continuing Operations-5.90-6.57-7.96-8.09-7.73-6.26-4.89-6.71
Net Income-5.90-6.57-7.96-8.09-7.73-6.26-4.89-6.71
EPS (Recurring)-0.39-0.64-0.86-0.87-0.84-0.70-0.56-0.80
EPS (Basic, Before Extraordinaries)-0.39-0.64-0.86-0.87-0.84-0.70-0.56-0.80
EPS (Diluted)-0.39-0.64-0.86-0.87-0.84-0.70-0.56-0.80
EBITDA-6.10-6.68-8.11-8.33-8.04-6.62-5.30-7.24
Non-Operating Income (Expense)0.210.110.150.240.320.360.410.53
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.310.360.350.300.290.500.360.34
Price To Sales Ratio5,145.9795.8617.4618.2412.157.238.552.02
Operating Margin----95,479.25-2,493.79-376.41-276.55-334.91
Net Margin----92,680.38-2,395.34-356.05-255.23-310.17
Shares Outstanding15.1213.539.269.259.259.258.708.70
Market Capitalization26.7841.9336.4873.1074.8554.7079.6319.31

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments20.8638.927.794.0937.3118.5214.187.998.90
Short Term Receivables0.432.250.920.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.271.911.260.060.510.260.470.920.77
Total Current Assets22.5643.089.964.1637.8218.7814.658.919.67
Net Property, Plant & Equipment0.000.000.000.000.000.300.500.350.46
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.00-0.000.008.648.648.6415.57
Deferred Tax Assets0.520.37--0.001.820.170.440.00
Other Assets0.320.000.010.000.020.020.320.300.45
Total Assets23.4043.469.974.1637.8429.5524.2818.6426.15
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.110.110.000.55
Accounts Payable1.451.510.660.100.950.551.250.200.51
Other Current Liabilities3.202.371.930.641.981.780.360.611.63
Total Current Liabilities4.663.882.600.742.932.441.720.802.69
Long Term Debt0.000.000.0036.700.000.040.140.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.520.37--0.002.262.292.222.22
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities5.184.252.6037.442.934.734.143.034.92
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity18.2239.207.38-33.2934.9124.8120.1315.6121.23
Total Shareholders Equity18.2239.207.38-33.2934.9124.8120.1315.6121.23
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity18.2239.207.38-33.2934.9124.8120.1315.6121.23
Total Liabilities & Stockholders Equity23.4043.469.974.1637.8429.5524.2818.6426.15
Book Value Per Share1.974.501.30-64.2425.6929.0745.10346.801,644.92
Tangible Book Value Per Share1.974.501.30-64.2425.6918.9525.75154.89438.67
Full-Time Employees15158131612101011
Price to Book Ratio1.540.424.520.430.892.050.770.432.69
Return on Assets-80.67-60.98-13.32-27.64-71.51-52.71-54.99-82.04-6.25
Return on Equity-93.92-69.95-15.74-713.60-80.69-63.12-66.02-99.72-8.97
Return on Invested Capital-147.98-41.56-29.44-169.87-69.02-57.08-58.21-117.67-6.43
Quick Ratio4.8411.113.845.6112.927.718.5111.093.59
Current Ratio4.8411.113.845.6112.927.718.5111.093.59

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-28.52-26.97-16.29-2.17-5.80-24.10-14.19-11.80-18.37
Depreciation----0.000.090.100.100.11
Other Funds (Non Cash)0.970.590.20-5.022.859.590.740.528.20
Funds from Operations-27.55-26.37-16.09-7.19-2.95-14.86-15.02-10.85-10.50
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.962.92-0.44-0.260.380.361.470.99-0.28
Cash from Operating Activities-26.59-23.45-16.53-7.45-2.57-14.50-13.55-9.86-10.77
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments4.6418.10-28.660.000.000.000.000.000.00
Purchase of Investments-20.56-25.40-48.100.000.000.000.000.000.00
Sale Or Maturity of Investments25.2043.5019.440.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities4.6418.10-28.660.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.574.5946.400.810.0033.3017.8916.0410.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.574.5946.400.810.0033.3017.8916.0410.42
Proceedsfrom Stock Options18.564.5946.400.810.0031.09-0.98-0.1610.42
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-0.55
Change in Long Term Debt0.000.000.000.000.000.000.000.00-0.55
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-0.55
Net Financing Active Other Cash Flow0.000.000.0010.340.000.000.000.000.00
Other Financing Activities Uses0.000.000.00-1.550.000.000.000.000.00
Cash from Financing Activities18.574.5946.4011.150.0033.3017.8916.049.87
Net Change in Cash-3.38-0.761.213.70-2.5718.804.346.19-0.91
Free Cash Flow-26.59-23.45-16.53-7.45-2.57-14.50-13.55-9.86-10.77
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-0.44-1.680.33-0.44

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments19.6024.9412.9220.8627.2933.53
Short Term Receivables0.000.000.000.431.362.36
Inventories0.000.000.000.000.000.00
Other Current Assets1.300.731.701.271.691.96
Total Current Assets20.9025.6714.6222.5630.3437.86
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets---0.52--
Other Assets0.430.320.490.320.270.22
Total Assets21.3325.9915.1123.4030.6138.08
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable1.620.692.271.451.351.85
Other Current Liabilities2.362.352.223.203.252.80
Total Current Liabilities3.973.034.504.664.604.64
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.52--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.973.034.505.184.604.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity17.3622.9610.6218.2226.0133.44
Total Shareholders Equity17.3622.9610.6218.2226.0133.44
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity17.3622.9610.6218.2226.0133.44
Total Liabilities & Stockholders Equity21.3325.9915.1123.4030.6138.08
Book Value Per Share1.151.701.151.972.813.61
Tangible Book Value Per Share1.151.701.151.972.813.61
Full-Time Employees---15--
Price to Book Ratio1.542.702.002.812.241.58
Return on Assets-109.81-94.73-111.89-80.67-64.37-49.55
Return on Equity-131.52-107.62-132.76-93.92-71.42-54.21
Return on Invested Capital-33.97-28.62-75.02-44.38-29.70-18.72
Quick Ratio5.268.473.254.846.608.16
Current Ratio5.268.473.254.846.608.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.90-6.57-7.96-8.09-7.73-6.26
Other Funds (Non Cash)0.200.340.280.150.070.26
Funds from Operations-5.70-6.23-7.69-7.93-7.66-6.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.62-0.69-0.331.361.19-0.52
Cash from Operating Activities-5.07-6.92-8.02-6.58-6.47-6.51
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-10.972.537.715.377.58-0.25
Purchase of Investments-12.47-2.47-0.99-4.63-3.92-9.75
Sale Or Maturity of Investments1.505.008.7010.0011.509.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-10.972.537.715.377.58-0.25
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.3618.910.010.000.004.59
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.3618.910.010.000.004.59
Proceedsfrom Stock Options-0.3618.910.000.000.004.59
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.3618.910.010.000.004.59
Net Change in Cash-16.4014.52-0.29-1.201.12-2.18
Free Cash Flow-5.07-6.92-8.02-6.58-6.47-6.51

Revenue breakdown

Pharmaceutical Preparations2024: 9.74M 2025: 4.01M
United States2024: 9.74M 2025: 4.01M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.50%1.2M9.7M289.99K
2026-10-1512.45%1.2M9.7M297.68K
2026-09-3013.81%1.3M9.7M361.67K
2026-09-1512.66%1.2M9.7M5.48M
2026-08-3113.71%1.3M9.7M5.55M
2026-08-149.92%1.0M9.7M5.60M
2026-07-3110.26%0.8M8.1M5.54M
2026-07-1510.20%0.8M8.1M5.58M
2026-06-3014.40%0.8M5.6M5.36M
2026-06-158.95%0.3M3.8M220.45K
2026-05-295.48%0.3M4.8M63.71K
2026-05-155.79%0.3M4.8M66.35K
2026-04-305.87%0.3M4.8M71.17K
2026-04-155.71%0.3M4.8M82.82K
2026-03-316.54%0.3M4.8M85.81K
2026-03-135.65%0.3M4.8M85.71K
2026-02-276.19%0.3M4.8M75.65K
2026-02-135.25%0.3M4.8M75.14K
2026-01-304.90%0.2M4.8M72.54K
2026-01-154.04%0.2M4.8M67.51K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-138-KCurrent report2026-10-12SEC
2026-10-098-KCurrent report2026-10-09SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-108-KCurrent report2026-09-10SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-07-10EFFECTEffectiveness filing by commission orderSEC
2026-07-10424B3SEC
2026-07-098-KCurrent report2026-07-09SEC
2026-07-08SCHEDULE 13G/ASEC
2026-07-06S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-26SCHEDULE 13GSEC
2026-06-228-KCurrent report2026-06-22SEC
2026-06-22424B5SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-06-188-KCurrent report2026-06-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-063.00M100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11737.72K1800

Institutional holders

Manager% owned
Woodline Partners LP5.09%
VANGUARD CAPITAL MANAGEMENT LLC2.34%
SABBY MANAGEMENT, LLC1.84%
GEODE CAPITAL MANAGEMENT, LLC0.61%
BlackRock, Inc.0.40%
Byrne Asset Management LLC0.33%
VANGUARD FIDUCIARY TRUST CO0.27%
CITIGROUP INC0.26%
CITIZENS FINANCIAL GROUP INC/RI0.25%
JANE STREET GROUP, LLC0.24%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.85%
VANGUARD EXTENDED MARKET INDEX FUND0.49%
Fidelity Extended Market Index Fund0.48%
iShares Micro-Cap ETF0.14%
Fidelity Total Market Index Fund0.06%
Fidelity Series Total Market Index Fund0.06%
Avantis U.S. Small Cap Equity ETF0.02%
Fidelity Nasdaq Composite Index Fund0.02%
1290 VT Micro Cap Portfolio0.01%

OakChart. CRVO. Cached 15 minutes.